Logo image of CVKD

CADRENAL THERAPEUTICS INC (CVKD) Stock Fundamental Analysis

USA - NASDAQ:CVKD - US1276362076 - Common Stock

13.62 USD
-0.57 (-4.02%)
Last: 10/10/2025, 9:19:31 PM
13.45 USD
-0.17 (-1.25%)
After Hours: 10/10/2025, 9:19:31 PM
Fundamental Rating

2

CVKD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. While CVKD has a great health rating, there are worries on its profitability. CVKD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CVKD has reported negative net income.
CVKD had a negative operating cash flow in the past year.
CVKD Yearly Net Income VS EBIT VS OCF VS FCFCVKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of CVKD (-235.98%) is worse than 91.33% of its industry peers.
With a Return On Equity value of -328.17%, CVKD is not doing good in the industry: 73.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -235.98%
ROE -328.17%
ROIC N/A
ROA(3y)-354.52%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CVKD Yearly ROA, ROE, ROICCVKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 -400 -600 -800

1.3 Margins

CVKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVKD Yearly Profit, Operating, Gross MarginsCVKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

CVKD has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CVKD Yearly Shares OutstandingCVKD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M
CVKD Yearly Total Debt VS Total AssetsCVKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -4.48, we must say that CVKD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.48, CVKD is in line with its industry, outperforming 41.33% of the companies in the same industry.
There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACCN/A
CVKD Yearly LT Debt VS Equity VS FCFCVKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M -5M

2.3 Liquidity

CVKD has a Current Ratio of 3.56. This indicates that CVKD is financially healthy and has no problem in meeting its short term obligations.
CVKD's Current ratio of 3.56 is fine compared to the rest of the industry. CVKD outperforms 60.20% of its industry peers.
CVKD has a Quick Ratio of 3.56. This indicates that CVKD is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.56, CVKD is doing good in the industry, outperforming 61.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.56
CVKD Yearly Current Assets VS Current LiabilitesCVKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.99% over the past year.
EPS 1Y (TTM)5.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CVKD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.73%
EPS Next 2Y26.61%
EPS Next 3Y16.04%
EPS Next 5Y13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVKD Yearly Revenue VS EstimatesCVKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 20M 40M 60M 80M 100M
CVKD Yearly EPS VS EstimatesCVKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVKD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVKD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVKD Price Earnings VS Forward Price EarningsCVKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVKD Per share dataCVKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

CVKD's earnings are expected to grow with 16.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.61%
EPS Next 3Y16.04%

More info and screens

0

5. Dividend

5.1 Amount

CVKD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (10/10/2025, 9:19:31 PM)

After market: 13.45 -0.17 (-1.25%)

13.62

-0.57 (-4.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners7.23%
Inst Owner Change0%
Ins Owners14.25%
Ins Owner Change-3.51%
Market Cap27.92M
Analysts82.5
Price Target39.27 (188.33%)
Short Float %0.79%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.88%
Min EPS beat(2)-24.94%
Max EPS beat(2)-14.82%
EPS beat(4)0
Avg EPS beat(4)-26.87%
Min EPS beat(4)-56.79%
Max EPS beat(4)-10.93%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.94%
PT rev (3m)7.94%
EPS NQ rev (1m)-4.07%
EPS NQ rev (3m)-8.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.49
P/tB 6.49
EV/EBITDA N/A
EPS(TTM)-8.88
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-5.69
FCFYN/A
OCF(TTM)-5.69
OCFYN/A
SpS0
BVpS2.1
TBVpS2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -235.98%
ROE -328.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-354.52%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.56
Quick Ratio 3.56
Altman-Z -4.48
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.89%
EPS Next Y17.73%
EPS Next 2Y26.61%
EPS Next 3Y16.04%
EPS Next 5Y13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.85%
EBIT Next 3Y-47.56%
EBIT Next 5Y-40.95%
FCF growth 1Y-108.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.41%
OCF growth 3YN/A
OCF growth 5YN/A